Advertisement

Ads Placeholder
Loading...

Biophytis S.A.

ALBPS.PAEURONEXT
Healthcare
Biotechnology
0.02
0.00(1.79%)
U.S. Market opens in 56h 8m

Biophytis S.A. Fundamental Analysis

Biophytis S.A. (ALBPS.PA) shows moderate financial fundamentals with a PE ratio of -0.04, profit margin of 0.00%, and ROE of 92.02%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

ROE92.02%
Cash Position366.56%
PEG Ratio-0.00

Areas of Concern

Operating Margin0.00%
Current Ratio0.35
We analyze ALBPS.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 51.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
51.7/100

We analyze ALBPS.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALBPS.PA struggles to generate sufficient returns from assets.

ROA > 10%
-1.21%

Valuation Score

Excellent

ALBPS.PA trades at attractive valuation levels.

PE < 25
-0.04
PEG Ratio < 2
-0.00

Growth Score

Moderate

ALBPS.PA shows steady but slowing expansion.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
84.06%

Financial Health Score

Moderate

ALBPS.PA shows balanced financial health with some risks.

Debt/Equity < 1
-1.00
Current Ratio > 1
0.35

Profitability Score

Weak

ALBPS.PA struggles to sustain strong margins.

ROE > 15%
92.02%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALBPS.PA Expensive or Cheap?

P/E Ratio

ALBPS.PA trades at -0.04 times earnings. This suggests potential undervaluation.

-0.04

PEG Ratio

When adjusting for growth, ALBPS.PA's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Biophytis S.A. at -0.04 times its book value. This may indicate undervaluation.

-0.04

EV/EBITDA

Enterprise value stands at 0.90 times EBITDA. This is generally considered low.

0.90

How Well Does ALBPS.PA Make Money?

Net Profit Margin

For every $100 in sales, Biophytis S.A. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $92.02 in profit for every $100 of shareholder equity.

92.02%

ROA

Biophytis S.A. generates $-1.21 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.21%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

ALBPS.PA converts -0.67% of its market value into free cash.

-0.67%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.04

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.04

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.35

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.92

vs 25 benchmark

ROA

Return on assets percentage

-1.21

vs 25 benchmark

ROCE

Return on capital employed

1.94

vs 25 benchmark

How ALBPS.PA Stacks Against Its Sector Peers

MetricALBPS.PA ValueSector AveragePerformance
P/E Ratio-0.0428.45 Better (Cheaper)
ROE92.02%763.00% Weak
Net Margin0.00%-45265.00% (disorted) Weak
Debt/Equity-1.000.34 Strong (Low Leverage)
Current Ratio0.352795.60 Weak Liquidity
ROA-121.24%-16588.00% (disorted) Weak

ALBPS.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Biophytis S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

99.56%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

99.54%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ